GSK Bets Big on Better Biological Data for AI
GSK just signed a new deal with a company called Relation Therapeutics. They want to improve how AI finds new drugs by using higher quality information. The partnership is worth up to 110 million dollars.
The main problem with many AI drug projects is that they lack good data. Relation will now build massive databases showing exactly how human cells react to different drugs and genetic changes. This creates a much clearer map for the AI to follow.
Better data leads to better results in the lab. By focusing on real biological reactions instead of guesses, the companies hope to build more reliable medicines. This shows that having the right information is more important than just having a fast computer.
Comments (0)
No comments yet. Be the first!
More AI news
NewsThe Real Cost of AI is People
Companies are spending more time fixing AI mistakes than they expected.
NewsAI Solves Quantum Secrets in Record Time
Two different research teams used the same AI model to solve a complex math problem on the same day.
NewsAlibaba releases massive new AI model
Alibaba is launching Qwen3.8-Max, a powerful model designed to handle complex projects over several days.